In patients who show substantial glycemic improvement but only modest weight loss after 6–12 months in a remote carbohydrate-reduction program, how do you choose between intensifying lifestyle components (dietary structure, coaching frequency, resistance training/PA prescription) versus adding or optimizing anti-obesity pharmacotherapy to pursue liver risk reduction?